Human Glypican-3 (GPC3) Antibody from EXALPHA BIOLOGICALS, INC.
Search, find, compare suppliers for anti-Human Glypican-3 (GPC3) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Human Glypican-3 (GPC3) |
| Clone | polyclonal |
| Host Species | Sheep |
| Reactive Species | human |
| Isotype | n/a |
| Format | purified |
| Size | 500 µg |
| Concentration | n/a |
| Applications | Immunohistochemistry (paraffin), Western Blotting, Immunohistochemistry (paraffin) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Sheep anti Human Glypican-3 (GPC3) |
| Immunogen | C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope) |
| Other Names | GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7 |
| Gene, Accession # | UniProt: P51654 |
| Catalog # | X2395P |
| Price | $319 |
| Order / More Info | Human Glypican-3 (GPC3) Antibody from EXALPHA BIOLOGICALS, INC. |
| Product Specific References | 1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222. 2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230. 3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223. 4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394. 5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224. 6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906. 7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711. 8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990. 9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326. |
EXALPHA BIOLOGICALS, INC.
EXALPHA BIOLOGICALS, INC.
2 Shaker Road, Unit B101
Shirley MA 01464
P: 978-425-1370
info@exalpha.com
https://www.exalpha.com
Profile of EXALPHA BIOLOGICALS, INC.
Return to Antibodies